US: Pharmaceuticals
featured
During a conference call on drugmaker Merck& Co.' s fourth-quarter results, executives discussed some of their experimental drugs in development, including suvorexant, a new type of insomnia medicine designed to limit the morning grogginess common with sleep aids. QUESTION: What prospects do you see for suvorexant if it's approved?
» Read MoreMore
-
During a conference call on drugmaker Merck& Co.' s fourth-quarter results, executives discussed some of their experimental drugs in development, including suvorexant, a new type of insomnia medicine designed to limit the morning grogginess common with sleep aids. QUESTION: What prospects do you see for suvorexant if it's approved?
-
Zoetis, the largest IPO of a U.S. company since Facebook, is showing strength.
-
Pfizer's animal health subsidiary Zoetis raised $2.2 billion in its public offering on Thursday, becoming the largest IPO from a U.S. company since Facebook.
-
Feb 1- Merck& Co Inc's quarterly results beat estimates, helped by strong sales of its Januvia diabetes drug and Gardasil vaccine against cervical cancer, but the company forecast 2013 profit at the low end of expectations. The No. 2 U.S. drugmaker said it earned $1.4 billion, or 46 cents per share, in the fourth quarter.
-
Severin Schwan, Roche CEO, discusses the company's future growth plans developing innovative medicines to fight the battle against cancer and Alzheimer disease.
-
Feb 1- Merck& Co's quarterly results beat forecasts, helped by strong sales of its Januvia diabetes drug and Gardasil vaccine against cervical cancer, but the company issued a full-year 2013 profit view at the low end of Wall Street expectations. The No. 2 U.S. drugmaker on Friday said it earned $1.4 billion, or 46 cents per share, in the fourth quarter.
-
Feb 1- Merck& Co's quarterly results beat forecasts, helped by strong sales of its Januvia diabetes drug and Gardasil vaccine against cervical cancer, but the company issued a full-year 2013 profit view at the low end of Wall Street expectations. The No. 2 U.S. drugmaker on Friday said it earned $1.4 billion, or 46 cents per share, in the fourth quarter.
-
Denmark is facing its "Nokia moment"; drugmaker Novo Nordisk has ballooned into a $100 billion giant, dominating its home stock market just as the Finnish firm did at the height of the 1990s tech boom.
-
Denmark is facing its "Nokia moment"; drugmaker Novo Nordisk has ballooned into a $100 billion giant, dominating its home stock market just as the Finnish firm did at the height of the 1990s tech boom.
-
Denmark is facing its "Nokia moment"; drugmaker Novo Nordisk has ballooned into a $100 billion giant, dominating its home stock market just as the Finnish firm did at the height of the 1990s tech boom.
-
*Quarterly sales $11.74 bln, vs view $11.48 bln. Feb 1- Merck& Co Inc's quarterly results beat estimates, but the drugmaker issued a cautious 2013 profit forecast and said it will delay seeking approval for a high-profile osteoporosis drug, sending its shares down 3 percent.
-
*Led probe into Google that ended with mild reprimand. WASHINGTON, Jan 31- The chairman of the Federal Trade Commission, Jon Leibowitz, said on Thursday he will step down in mid-February after a tenure famous for a probe of allegations that Google manipulated search results that resulted in a mild reprimand for the technology company.
-
Jan 31- Pfizer Inc's animal health subsidiary Zoetis raised $2.2 billion in its public offering on Thursday, becoming the largest IPO from a U.S. company since Facebook. Zoetis' over $2 billion public offering is the largest from a U.S. company since Facebook raised $16 billion last May.
-
WASHINGTON-- Shares of Halozyme Therapeutics tumbled 8 percent Thursday after a Wall Street analyst downgraded the specialty drugmaker, saying that European regulators may not approve a key cancer drug this year.
-
Jan 31- Ben Venue Laboratories Inc., a unit of German drug company Boehringer Ingelheim, may not freely make or distribute drugs from its facility in Bedford, Ohio, until U.S. regulators have determined it is in compliance with good manufacturing standards. Ben Venue has repeatedly violated good manufacturing practices, the FDA said in a statement.
-
CAMP HILL, Pa.-- The flu helped Rite Aid Corp. sales in established stores rise slightly in January, although generic drugs continued to hurt the drugstore chain's pharmacy sales.
-
*Q4 sales $7.28 billion, vs I/B/E/S consensus $7.20 bln. *Q4 core EPS $1.56 vs $1.35, helped by tax adjustment. LONDON, Jan 31- AstraZeneca's new boss said sales and profits would both fall sharply in 2013 as the drugmaker struggles to turn itself around by investing more in-house and on potential acquisitions.
-
BRUSSELS, Jan 31- EU antitrust regulators stepped up their fight against companies blocking the market entry of cheaper generic medicines, with charges against Johnson& Johnson and Novartis over a pay-for-delay deal in the Netherlands.
-
BRUSSELS, Jan 31- EU antitrust regulators charged pharmaceutical firms Johnson& Johnson and Novartis on Thursday over the delay of a generic competitor for painkiller fentanyl in the Dutch market.
-
*Q4 sales $7.28 billion, vs I/B/E/S consensus $7.20 bln. *Q4 core EPS $1.56 vs $1.35, helped by tax adjustment. LONDON, Jan 31- AstraZeneca's new boss said the drugmaker faced a tough year, with sales expected to fall by a mid-to-high single digit percentage rate as patent expiries continued to erode business.